

Invited Mini Review

Non-classical role of Galectin-3 in cancer progression: translocation to nucleus by carbohydrate-recognition independent manner

Seok-Jun Kim^{1,2} & Kyung-Hee Chun^{3,4,*}

¹Department of Biomedical Science, College of Natural Science, Chosun University, ²Department of Life Science & Brain Korea 21 Plus Research Team for Bioactive Control Technology, Chosun University, Gwangju 61452, ³Department of Biochemistry & Molecular Biology, Yonsei University College of Medicine, ⁴Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul 03722, Korea

Galectin-3 is a carbohydrate-binding protein and regulates diverse functions, including cell proliferation and differentiation, mRNA splicing, apoptosis induction, immune surveillance and inflammation, cell adhesion, angiogenesis, and cancer-cell metastasis. Galectin-3 is also recommended as a diagnostic or prognostic biomarker of various diseases, including heart disease, kidney disease, and cancer. Galectin-3 exists as a cytosol, is secreted in extracellular spaces on cells, and is also detected in nuclei. It has been found that galectin-3 has different functions in cellular localization: (i) Extracellular galectin-3 mediates cell attachment and detachment. (ii) cytosolic galectin-3 regulates cell survival by blocking the intrinsic apoptotic pathway, and (iii) nuclear galectin-3 supports the ability of the transcriptional factor for target gene expression. In this review, we focused on the role of galectin-3 on translocation from cytosol to nucleus, because it happens in a way independent of carbohydrate recognition and accelerates cancer progression. We also suggested here that intracellular galectin-3 could be a potent therapeutic target in cancer therapy. [BMB Reports 2020; 53(4): 173-180]

INTRODUCTION

Galectin-3, as a member of the galectin family, which are recognized β -galactoside-containing glycoconjugates by means of carbohydrate-recognition domain (CRD) (1, 2). Based on molecular structure, galectin family consists of the 15 members and these family are divided into three main groups: 1)

prototype group (Galectin-1, -2, -5, -7, -10, -11, -13, -14, and -15), 2) tandem repeat group (galectin-4, -6, -8, -9, and -12), and 3) chimera type (galectin-3) (1, 3-6). Whereas prototype galectins are mostly homodimers with two polypeptides each containing a CRD, the tandem repeat galectins have two CRDs, connected by a linker region (1, 4, 5). Chimeric galectin-3 consist of one CRD connected to an extended Proline-Glycine-Tyrosine tandem repeats region and an N-terminal proline and glycine rich domain (3, 5). Galectin family are present in a various tissues, whereas others have a more specific location (1). Galectins have many functions, such as cell proliferation and differentiation, immune response, apoptosis, cancer progression, and metastasis (4, 7). The mechanisms underlying these aspects are currently the focus of massive research projects.

Galectin-3 is the only chimera type in animal lectins. Also, galectin-3 is one of the most studied of the galectin family, (8-10). It is a versatile 29–35 kDa protein, as an involved in multifil biological processes followed in cellular location: cell adhesion, cell growth and differentiation, the cell cycle, and apoptosis (1, 11, 12). Galectin-3 is situated on chromosome 14, locus q21–q22 which is coded by a single gene *LGALS3* (13). *LGALS3* gene promoter region have a several regulatory elements, like a Sp1 binding sites, AP-1 complex, cAMP-dependent response element (CRE) motifs, and two NF- κ B-like sites (10, 11). Galectin-3 mainly exists in the cytosol and is secreted out to the extracellular membrane (ECM) (14), but galectin-3 is also reported in the nucleus and mitochondria (9, 15).

In galectin family, it is known that there is no signal peptide to guide you through the classical secretion pathway. In particular, galectin-3 to go in extracellular space can interact with multiple binding partners or generality polylectosamine-rich molecules in the extracellular matrix (ECM) or on the surface of cells, and plays a major role in the extracellular regulation of various cancer progression (5, 16, 17). The non-classical secretion mechanism for galectin-3 remains unclear, but recently acquired data show that the secreted galectin-3 is regulated by

*Corresponding author. Tel: +82-2-2228-1699; Fax: +82-2-312-5041; E-mail: khchun@yuhs.ac

<https://doi.org/10.5483/BMBRep.2020.53.4.020>

Received 20 January 2020

Keywords: Cancer progression, Carbohydrate-binding, Cellular localization, Galectin-3

exosomes (18) and that the N-terminal domain serves to position the galectin-3 in these structures (6, 10, 19).

Galectin-3 is also present in the nucleus and cytosol. Especially, depending on the various cell types and specific experimental conditions, galectin-3 has been reported to be predominantly located in the cytosol and nuclei or distributed between the two subcellular compartments (1, 20). Many articles have supported galectin-3 localization, transport, and association with the interaction of distinct subcellular components (1, 20).

Through the in this review, we were described brief overview of the intracellular galectin-3 functions in cancer progression that are independent of carbohydrate recognition and nucleus or cytoplasmic shuttling.

REGULATION OF GALECTIN-3 EXPRESSION IN CANCERS

Despite of expression of galectin-3 in various of tissues and cell types, and their involvement in various human diseases, this molecule is of particular interest due to its remarkable role in controlling cancer progression (21, 22). Galectin-3 is often high expressed in various solid and malignant tumors, and this case is generally correlated with the progression of cancer, suggesting that this molecule plays an important role in disease outcome (4, 5). In particular, the expression of galectin-3 in cells is characterized by the following malignant cell transformation (23), tumor growth (24), cell adhesion (25), anoikis resistance (26, 27), pro- or anti-apoptosis (28-30), angiogenesis (31-33), and cell motility (34-36) have been reported. Galectin-3 expression may also be a potential biomarker of various cancers (37). Interestingly, expression of galectin-3 was implicated in many cancers (16, 38). Especially, highly expression of galectin-3 was detected in stomach, liver, esophagus, thyroid, and pancreas cancers (23, 39-44). This highly expressed galectin-3 is correlated with cancer progression or metastatic potential in various cancers (38, 45). However, contradictory results have also been reported, in which the expression of galectin-3 was significantly reduced in breast, prostate and endometrial cancers (46-49). In addition, expression of galectin-3 has also been reported to be up-regulated at an early stage of intrahepatic cholangiocarcinoma and down-regulated at later stage of intrahepatic cholangiocarcinoma (50). Also, galectin-3 translocation from the nucleus to the cytoplasm during prostate carcinoma was observed (51). This implies that decreased galectin-3 expression may be associated with alterations in cytoplasm / nucleus expression patterns and provides a reason why studies on translocation as well as the expression of galectin-3 in various carcinomas should be continued.

According to many reports, galectin-3 is not a common and obvious marker for various cancers, but it can be a useful parameter for diagnosis many tumors. Also, both transcriptional and translational galectin-3 expression was regulated by various stimulations and ligands. In addition, numerous factors have an effect on the complex regulatory mechanism of galectin-3

(1, 7). For example, the expression of galectin-3 in adenoma that prolactin and adrenocorticotropic hormone (ACTH) in the pituitary gland and other tumors is associated with the galectin-3's promoter methylation status of the galectin-3 (52). Also, regulatory mechanism of galectin-3 expression is not directly induced by certain factors, but the cellular differentiation state or tissue type has been involved. Moreover, various transcription factors, as a RUNX (rent-related protein) family, nuclear factor kB (NF-kB), homeodomain-interacting protein kinase 2 (HIPK2), and many intracellular signal pathways, such as Wnt and Notch signaling, are regulated in the regulation of galectin-3 expression (11, 53-56).

MECHANISM OF NUCLEUS AND CYTOPLASMIC GALECTIN-3 SHUTTLING

Nucleus and cytoplasmic shuttling is generally reported as the repeated bi-directional movement of proteins across nuclear pore complex (7, 20, 57). Both nucleus and cytoplasmic shuttling of galectin-3 reported by means of the many articles (57, 58). The galectin-3 movement between the nucleus and the cytoplasm has been the focus of attention for years (7, 17, 20). This is because the shuttle of galectin-3 from the nucleus to the cytoplasm is necessary because it protects certain cells from stress challenges (20, 57). Especially, the N-terminal area containing the phosphorylated Ser⁶ site, plays an important role in nuclear transport because the mutation in the Ser⁶ interferes with the export of galectin-3 by cytoplasm (1, 12, 59). CRD of galectin-3 is important for carbohydrate bonding, but this structural domain is also important for galectin-3 localization in cells (1, 7, 12). Recently, galectin-3 is seen as an important nuclear protein, which may be evidenced by the discovery of both nuclear import sequences (nuclear localization sequence; NLS) and nuclear export sequences (NES) sequences within the CRD (Fig. 1) (1, 4, 20). The combination with Importin α is very important for the movement of galectin-3 but the Importin α/β complex is necessary for the transport of galectin-3 (60, 61). Also, export of galectin-3 is known to rely on the binding to Nucleoporin 98 (Nup98), and the Nup98:XPO1 complex is involved in the nuclear migration of galectin-3 (62).

Also, a mutation of galectin-3 at position 64 of amino-acid (rs4644) substituting proline for histidine (gal-3H⁶⁴) increased nuclear galectin-3 in breast and gastric cancers (63, 64). Moreover, gal-3H⁶⁴ enhances gastric cancer progression more than wild type galectin-3 (gal-3P⁶⁴) does. gal-3H⁶⁴ also increased both nuclear accumulation of β -catenin and expression of TCF-4 target genes, such as fascin-1 and c-Myc, by means of the augmented promoter-binding activity of TCF-4 more than did gal-3P⁶⁴ (63). Thus, galectin-3 shuttling was regulated by the domain or mutation in various cancers and was involved in cancer progression.




Fig. 1. Structure of galectin-3. Galectin-3 consists of an N-terminal Domain (NTD), which has an N-terminal Region of 12 amino acids (aa) and a PGAY repeat motif (12-115aa). The carbohydrate-recognition domain (CRD) 130 aa comprises the C-terminal. Each domain describes a binding motif and signaling pathway.

Apoptosis regulated by galectin-3 interacts with carbohydrate recognition independent manner

Galectin-3 involved in diverse signal-transduction cascades and pro- or anti-survival processes. Actually, phosphorylated galectin-3 is required for anti-apoptotic activity and for phosphorylation regulated by carbohydrate recognition (9, 12, 17). However, those anti-apoptotic functions of galectin-3 were regulated by non-carbohydrate recognition. It was proved that galectin-3 interacts Bcl-2 (28). Although galectin-3 is not a member included in the Bcl-2 family, interestingly, these galectin-3 and Bcl-2 genes have significant sequence similarity (48% protein sequence similarity) (28). Especially, CRD region of galectin-3 have a four-amino-acid motif, as an Asn-Trp-Gly-Arg (NWGR) (amino-acid residues 180-183), which motif is highly conserved in Bcl-2 family's BH-1 domain (amino-acid residues 143-146 in Bcl-2 gene) (12, 28). Moreover, galectin-3 is the only member that contains the NWGR motif in the galectin family and that acts as an anti-apoptotic molecule in intracellular localization. Therefore, the NWGR motif in CRD of galectin-3 is closely involved in anti-apoptotic process through interaction with Bcl-2. However, galectin-3 regulates apoptosis by means of the cytochrome c release and cell-cycle regulation.

Cancer progression and cell motility regulated by galectin-3 interacts with carbohydrate recognition independent manner

As mentioned in the introduction, galectin-3 has many roles in various cancers, such as splicing (65), cell proliferation (66), regulation of the cell cycle (26), angiogenesis (33), tumorigenesis (67), and cancer metastasis (68). It has also been demonstrated to be highly expressed in various primary and metastatic tumors (69) associated with increased cancer progression, cell motility, and metastasis (4, 70). Actually, galectin-3 binding with transcription factor (TF) in the nucleus by means of the following signaling pathway, such as Wnt, Ras, or MEK, as followed various cancer progression (1, 4). In this part, we showed that the role of galectin-3 in cancer progression and cell motility with regulation of gene transcription focuses on our galectin-3-related story.

Galectin-3 and Fascin-1: For the cancer progression and cell motility with galectin-3, we focus on motility-related genes, among which fascin-1, an actin-bundling protein, is located

along the entire length of filopodia in cells (71, 72). Because (a) a highly expressed fascin-1 was reported in various cancers including gastric, lung, and esophagus cancers (73-75). (b) Increased fascin-1 induces membrane protrusions and increases cancer cell motility (76). (c) Depletion of fascin-1 leads to a substantially reduced number of filopodia and overexpression of fascin-1, significantly increasing cell migration (74, 77, 78). Especially, fascin-1 expression is regulated by the Wnt-signaling pathway. As previously reported, galectin-3 was also reported to interact with GSK-3b and b-catenin which is regulate Wnt signaling (79). Therefore, galectin-3 regulates b-catenin nuclear accumulation via strongly interacting with GSK-3b and the binding of b-catenin/TCF-4 to promoter region of fascin-1 (Fig. 2) (35). Those studies propose that galectin-3 is involved in gastric-cancer metastasis and a critical therapeutic target for the cancer prevention.

Galectin-3 and Protease-activated receptor-1 (PAR-1), Matrix Metalloprotease (MMP)-1: PAR-1, a cell-surface receptor, is a member of the family of transmembrane G-protein-coupled receptors (80). Activated PAR-1 is initiated by cleavage at its N terminus exodomain between Arg41 and Ser42, and autophosphorylates to trigger amplification of downstream signaling by proteases (80-83), such as thrombin or MMP-1 derived from stroma (84). PAR-1 and MMP-1 were related in cancer progression and cell motility. Interestingly, up-regulation of PAR-1 and MMP-1 via c-Jun and Fra-1 over-expression also followed, AP-1 complex, as a c-Jun and Fra-1, were direct interaction of galectin-3 (Fig. 2). It was previously reported that galectin-3 regulates MUC2 expression via interaction with AP-1, leading to its activation, and the site of formation of complexes was hypothesized to be AP-1 on the MUC2 promoter (85). Those results also support about galectin-3 regulates cancer progression and motility.

Galectin-3 and Neogenin-1: Neogenin-1 is a transmembrane receptor, as a member of immunoglobulin superfamily (86). Although neogenin-1 has significant sequence similarity (50% amino-acid identity) with the tumor suppressor molecule deleted in colon cancer (DCC) (86), but the expression is increased in gastric cancer patients (87). Also, neogenin-1 is enhanced in cancer proliferation and cell motility (87). Actually, expression of neogenin-1 is regulated by heat shock factor-1 (HSF-1). Moreover, galectin-3 promotes gastric-cancer




Fig. 2. Schematic model of mechanism of galectin-3 in cancer progression and metastasis. Galectin-3 bound various transcription factors, such as AP-1, HSF-1, C/EBP β , and TCF4/LEF1, and regulates cancer progression and cell motility.

cell motility by means of up-regulation of neogenin-1 expression by means of the induced phosphorylation of ROCK1(87). Additionally, galectin-3 induced accumulation of HSF-1 in nuclei by means of direct binding (Fig. 2). Those data suggest that galectin-3 is involved in cancer progression.

Galectin-3 and Hyaluronan-mediated motility receptor (HMMR):

At last, HMMR binds with hyaluronan on the cell surface, where it activates a signal-transduction cascade causing intracellular protein tyrosine phosphorylation (88, 89). In addition, HMMR interacts with actin filaments, microtubules, and mitotic spindle assemblies, necessary for the organization of the cytoskeletal network (88, 90-92). These HMMRs are regulated by interaction between the transcriptional factor CCAAT/enhancer-binding protein b (C/EBPb) and galectin-3 (36). Also, C/EBPb is regulated by galectin-3BP (galectin-3 binding protein) and promotes tumor progression in various cancers (Fig. 2) (93-95). These data mean galectin-3 binds with transcription factor in nuclei and regulates cancer progression and metastasis.

Senescence regulated by galectin-3 interacts with carbohydrate recognition independent manner

By means of the aberrant activation of oncogenes, such as Ras and Myc, or excessive mitogenic signals, can enhance senescence by means of two different pathways, p14^{ARF}/p53/p21 or p16^{INK4A}/pRB (96). However, galectin-3 knock-out (KO) mouse embryo fibroblasts (MEF) and silenced galectin-3 gastric-cancer cells showed that galectin-3 relies on p27^{KIP1}, not p21^{wAF1/CIP1}, to regulate premature senescence without oncogenic stress (97). Actually, the N-terminal of galectin-3 (amino-acid residues 1-110), bound with Rb, E2F1, as a transcription factor of SKP2, was released from Rb and initiated its transcriptional functions (Fig. 1) (97). Increased

SKP2 regulates p27^{KIP1} degradation. Based on the research, galectin-3 prevents premature senescence by means of interaction and phosphorylation of Rb and consequent regulation of SKP2 and p27^{KIP1} expression. Moreover, galectin-3 bound to human Telomerase Reverse Transcriptase (hTERT) is an important factor of tumorigenesis and senescence (98). Especially, hTERT plays an important role in the regulation of telomerase activity in cell division, which is responsible for immortalized cell growth. The hTERT was binding with the N-terminal of galectin-3 (amino-acid residues 1-62) and increased telomeric activity (Fig. 1) (98). This evidence will show that galectin-3 regulates cellular senescence by means of the related genes interaction.

Cancer stemness regulated by galectin-3 interacts with carbohydrate recognition independent manner

Cancer Stem Cells (CSCs) are a malignant and aggressive cancer phenotype and have been increasingly studied over the last decade. These cells are derived from more differentiated cancer cells, potentially acquiring self-renewal properties and the ability to undergo epithelial-mesenchymal metastasis (EMT). Recently, galectin-3 expression increased in tumor sphere formation in cancer cells, together with stem-cell markers Oct4, Sox2, Nanog, CD133, and CXCR4 (99). Those mean galectin-3 is involved in the stemness of cancer cells. Especially, galectin-3 binds with EGF and bFGF (99) as a component of stem-cell culture medium and regulates KLF4 expression with miRNA-152 (100). These results support that galectin-3 is involved in cancer stemness. Also, galectin-3 supports stemness by signaling pathway regulation. Galectin-3 was essential for cluster formation using $\alpha\beta3$ integrin and KRAS to activate the NF- κ B pathway and stemness (101). Also, the Wnt, Notch, and SHH signaling pathways can help CSCs properties from

normal stem cells. Among the signaling pathways, the Notch 1 intra-cellular domain (N1ICD) interacts with CRD of galectin-3 (amino-acid residues 111-250) (Fig. 1) in the cytoplasm of ovarian cancer cells (55). Moreover, galectin-3 is interaction with β -catenin, as a component Wnt signaling pathway, in the cytoplasm and help to nuclear accumulation in the gastric cancer cells (35, 63). The above results suggest that galectin-3 regulates cancer stemness by means of the various interaction molecules, not only carbohydrates.

PERSPECTIVES: GALECTIN-3 IS A POTENTIAL THERAPEUTIC TARGET FOR CANCER PROGRESSION

Among current research on the role of galectin-3, the prognosis value of cancer patients still needs to be discussed (5, 102). Nevertheless, the expression of galectin-3 was proved to be a useful parameter for the diagnosis and/or prognosis of various cancers. (21, 38, 103). Therefore, many researchers have attempted to develop new approaches for the diagnosis and treatment of cancer by galectin-3 targeting. First, transfected galectin-3 antisense cDNA decreases in the malignant phenotype of thyroid gland cancer cells (104). Numerous studies have focused on the galectin-3 targeting inhibitors, including peptide antagonists (105) and galactose-based inhibitors (106, 107). Also, in addition to these synthetic molecules, a natural product, pectin, has emerged as a good source for generating high-affinity galectin-3 inhibitors with low toxicity. Recently, a wide range of sub-molecular inhibitors have been considered (108). Among these, a new kind of galectin-3 inhibitor, which contains only one residue of sugar (109) that constitutes membrane permeability and oral available powerful galectin-3 inhibitor has been developed.

CONCLUSION

Highly expressed galectin-3 is detected in various cancers and tissues, and is involved in many biological processes, like a cell proliferation, adhesion, anti- or pro-apoptosis, cancer progression, and metastasis. Therefore, galectin-3 is enhanced in cancer progression and metastasis by means of different mechanisms. Also, the biological function of galectin-3 were attributed to each carbohydrate-binding activity. However, many articles showed that galectin-3 interacts with many molecules by non-carbohydrate binding. In this review, we focus on the regulation mechanism with nucleus and cytoplasmic shuttling and the role of nuclear galectin-3 in cancer progression. Especially, galectin-3 has an NLS and NES; however, galectin-3 mutation also helps the galectin-3 shuttling nucleus and cytosol. As follows, galectin-3 has many functions in each location. Additionally, galectin-3 is involved in cancer progression and metastasis by means of the binding with transcription factor, such as AP-1 complex (c-Jun/Fra-1), HSF-1, C/EBP β , and TCF4/LEF1. Also, recently many articles supported about multi-function of galectin-3 in various cancers and other diseases.

Those increased understanding evidences give to the galectin-3 expression or activity regulation mechanism for therapeutic purposes. Given these results, we propose that galectin-3 is a core protein in cancer progression and metastasis. In addition, the function of galectin-3 and the mechanisms by which it can be regulated should be understood in detail.

ACKNOWLEDGEMENTS

This work was supported by from the National Research Foundation (NRF) of Korea grants, funded by the Korean government (NRF-2017R1C1B2005265, NRF-2017R1A2B2006238, NRF-2019R1A2C2089237), the Bio & Medical Technology Development Program, MSIP (NRF-2015M3A9B6073835), KBRI basic research program through Korea Brain Research Institute funded by Ministry of Science and ICT(20-BR-03-02), and the International Research & Development Program of the NRF, funded by the Ministry of Education, Science and Technology (MEST) of Korea (NRF-2016K1A3A1A47921595).

CONFLICTS OF INTEREST

The authors have no conflicting interests.

REFERENCES

1. Dunic J, Dabelic S and Flogel M (2006) Galectin-3: an open-ended story. *Biochim Biophys Acta* 1760, 616-635
2. Leffler H, Carlsson S, Hedlund M, Qian Y and Poirier F (2002) Introduction to galectins. *Glycoconj J* 19, 433-440
3. Drickamer K and Fadden AJ (2002) Genomic analysis of C-type lectins. *Biochem Soc Symp* 69, 59-72
4. Liu FT and Rabinovich GA (2005) Galectins as modulators of tumour progression. *Nat Rev Cancer* 5, 29-41
5. Fortuna-Costa A, Gomes AM, Kozlowski EO, Stelling MP and Pavao MS (2014) Extracellular galectin-3 in tumor progression and metastasis. *Front Oncol* 4, 138
6. Hirabayashi J and Kasai K (1993) The family of metazoan metal-independent beta-galactoside-binding lectins: structure, function and molecular evolution. *Glycobiology* 3, 297-304
7. Johannes L, Jacob R and Leffler H (2018) Galectins at a glance. *J Cell Sci* 131
8. Argueso P and Panjwani N (2011) Focus on molecules: galectin-3. *Exp Eye Res* 92, 2-3
9. Ruvolo PP (2016) Galectin 3 as a guardian of the tumor microenvironment. *Biochim Biophys Acta* 1863, 427-437
10. Kadrofske MM, Openo KP and Wang JL (1998) The human LGALS3 (galectin-3) gene: determination of the gene structure and functional characterization of the promoter. *Arch Biochem Biophys* 349, 7-20
11. Wang L and Guo XL (2016) Molecular regulation of galectin-3 expression and therapeutic implication in cancer progression. *Biomed Pharmacother* 78, 165-171
12. Krzeslak A and Lipinska A (2004) Galectin-3 as a multifunctional protein. *Cell Mol Biol Lett* 9, 305-328

13. Raimond J, Zimonjic DB, Mignon C et al (1997) Mapping of the galectin-3 gene (LGALS3) to human chromosome 14 at region 14q21-22. *Mamm Genome* 8, 706-707
14. Hughes RC (1999) Secretion of the galectin family of mammalian carbohydrate-binding proteins. *Biochim Biophys Acta* 1473, 172-185
15. Yu F, Finley RL Jr, Raz A and Kim HR (2002) Galectin-3 translocates to the perinuclear membranes and inhibits cytochrome c release from the mitochondria. A role for synexin in galectin-3 translocation. *J Biol Chem* 277, 15819-15827
16. van den Brule F, Califice S and Castronovo V (2002) Expression of galectins in cancer: a critical review. *Glycoconj J* 19, 537-542
17. Ochieng J, Furtak V and Lukyanov P (2002) Extracellular functions of galectin-3. *Glycoconj J* 19, 527-535
18. Inohara H and Raz A (1994) Identification of human melanoma cellular and secreted ligands for galectin-3. *Biochem Biophys Res Commun* 201, 1366-1375
19. Yang RY, Rabinovich GA and Liu FT (2008) Galectins: structure, function and therapeutic potential. *Expert Rev Mol Med* 10, e17
20. Haudek KC, Spronk KJ, Voss PG, Patterson RJ, Wang JL and Arnoys EJ (2010) Dynamics of galectin-3 in the nucleus and cytoplasm. *Biochim Biophys Acta* 1800, 181-189
21. Thijssen VL, Heusschen R, Caers J and Griffioen AW (2015) Galectin expression in cancer diagnosis and prognosis: A systematic review. *Biochim Biophys Acta* 1855, 235-247
22. Ebrahim AH, Alalawi Z, Mirandola L et al (2014) Galectins in cancer: carcinogenesis, diagnosis and therapy. *Ann Transl Med* 2, 88
23. Takenaka Y, Inohara H, Yoshii T et al (2003) Malignant transformation of thyroid follicular cells by galectin-3. *Cancer Lett* 195, 111-119
24. Markowska AI, Jefferies KC and Panjwani N (2011) Galectin-3 protein modulates cell surface expression and activation of vascular endothelial growth factor receptor 2 in human endothelial cells. *J Biol Chem* 286, 29913-29921
25. Hughes RC (2001) Galectins as modulators of cell adhesion. *Biochimie* 83, 667-676
26. Kim HR, Lin HM, Biliran H and Raz A (1999) Cell cycle arrest and inhibition of anoikis by galectin-3 in human breast epithelial cells. *Cancer Res* 59, 4148-4154
27. Zhao Q, Barclay M, Hilkens J et al (2010) Interaction between circulating galectin-3 and cancer-associated MUC1 enhances tumour cell homotypic aggregation and prevents anoikis. *Mol Cancer* 9, 154
28. Yang RY, Hsu DK and Liu FT (1996) Expression of galectin-3 modulates T-cell growth and apoptosis. *Proc Natl Acad Sci U S A* 93, 6737-6742
29. Harazono Y, Kho DH, Balan V et al (2014) Galectin-3 leads to attenuation of apoptosis through Bax heterodimerization in human thyroid carcinoma cells. *Oncotarget* 5, 9992-10001
30. Nakahara S, Oka N and Raz A (2005) On the role of galectin-3 in cancer apoptosis. *Apoptosis* 10, 267-275
31. Nangia-Makker P, Wang Y, Raz T et al (2010) Cleavage of galectin-3 by matrix metalloproteases induces angiogenesis in breast cancer. *Int J Cancer* 127, 2530-2541
32. Wang LF, Liu YS, Yang B et al (2018) The extracellular matrix protein mindin attenuates colon cancer progression by blocking angiogenesis via Egr-1-mediated regulation. *Oncogene* 37, 601-615
33. Nangia-Makker P, Honjo Y, Sarvis R et al (2000) Galectin-3 induces endothelial cell morphogenesis and angiogenesis. *Am J Pathol* 156, 899-909
34. Kim SJ, Shin JY, Lee KD et al (2011) Galectin-3 facilitates cell motility in gastric cancer by up-regulating protease-activated receptor-1 (PAR-1) and matrix metalloproteinase-1 (MMP-1). *PLoS One* 6, e25103
35. Kim SJ, Choi IJ, Cheong TC et al (2010) Galectin-3 increases gastric cancer cell motility by up-regulating fascin-1 expression. *Gastroenterology* 138, 1035-1045 e1031-1032
36. Kang HG, Kim WJ, Kang HG, Chun KH and Kim SJ (2020) Galectin-3 interacts with C/EBPbeta and upregulates hyaluronan-mediated motility receptor expression in gastric cancer. *Mol Cancer Res* 18, 403-413
37. Dong R, Zhang M, Hu Q et al (2018) Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review). *Int J Mol Med* 41, 599-614
38. Califice S, Castronovo V and Van Den Brule F (2004) Galectin-3 and cancer (Review). *Int J Oncol* 25, 983-992
39. Baldus SE, Zirbes TK, Weingarten M et al (2000) Increased galectin-3 expression in gastric cancer: correlations with histopathological subtypes, galactosylated antigens and tumor cell proliferation. *Tumour Biol* 21, 258-266
40. Volante M, Bozzalla-Cassione F, Orlandi F and Papotti M (2004) Diagnostic role of galectin-3 in follicular thyroid tumors. *Virchows Arch* 444, 309-312
41. Gudowska M, Gruszewska E, Cylwik B et al (2015) Galectin-3 Concentration in Liver Diseases. *Ann Clin Lab Sci* 45, 669-673
42. Inufusa H, Nakamura M, Adachi T et al (2001) Role of galectin-3 in adenocarcinoma liver metastasis. *Int J Oncol* 19, 913-919
43. Honjo Y, Inohara H, Akahani S et al (2000) Expression of cytoplasmic galectin-3 as a prognostic marker in tongue carcinoma. *Clin Cancer Res* 6, 4635-4640
44. Shimamura T, Sakamoto M, Ino Y et al (2002) Clinicopathological significance of galectin-3 expression in ductal adenocarcinoma of the pancreas. *Clin Cancer Res* 8, 2570-2575
45. Sciacchitano S, Lavra L, Morgante A et al (2018) Galectin-3: One Molecule for an Alphabet of Diseases, from A to Z. *Int J Mol Sci* 19, pii: E379
46. Castronovo V, Van Den Brule FA, Jackers P et al (1996) Decreased expression of galectin-3 is associated with progression of human breast cancer. *J Pathol* 179, 43-48
47. Honjo Y, Nangia-Makker P, Inohara H and Raz A (2001) Down-regulation of galectin-3 suppresses tumorigenicity of human breast carcinoma cells. *Clin Cancer Res* 7, 661-668
48. Pacis RA, Pilat MJ, Pienta KJ et al (2000) Decreased galectin-3 expression in prostate cancer. *Prostate* 44, 118-123

49. Brustmann H, Riss D and Naude S (2003) Galectin-3 expression in normal, hyperplastic, and neoplastic endometrial tissues. *Pathol Res Pract* 199, 151-158
50. Shimonishi T, Miyazaki K, Kono N et al (2001) Expression of endogenous galectin-1 and galectin-3 in intrahepatic cholangiocarcinoma. *Hum Pathol* 32, 302-310
51. van den Brule FA, Waltregny D, Liu FT and Castronovo V (2000) Alteration of the cytoplasmic/nuclear expression pattern of galectin-3 correlates with prostate carcinoma progression. *Int J Cancer* 89, 361-367
52. Jin L, Riss D, Ruebel K et al (2005) Galectin-3 Expression in Functioning and Silent ACTH-Producing Adenomas. *Endocr Pathol* 16, 107-114
53. Shimura T, Takenaka Y, Fukumori T et al (2005) Implication of galectin-3 in Wnt signaling. *Cancer Res* 65, 3535-3537
54. Itoh K, Brott BK, Bae GU, Ratcliffe MJ and Sokol SY (2005) Nuclear localization is required for Dishevelled function in Wnt/beta-catenin signaling. *J Biol* 4, 3
55. Kang HG, Kim DH, Kim SJ et al (2016) Galectin-3 supports stemness in ovarian cancer stem cells by activation of the Notch1 intracellular domain. *Oncotarget* 7, 68229-68241
56. Pikarsky E, Porat RM, Stein I et al (2004) NF-kappaB functions as a tumour promoter in inflammation-associated cancer. *Nature* 431, 461-466
57. Davidson PJ, Davis MJ, Patterson RJ, Ripoche MA, Poirier F and Wang JL (2002) Shuttling of galectin-3 between the nucleus and cytoplasm. *Glycobiology* 12, 329-337
58. Arnoys EJ, Ackerman CM and Wang JL (2015) Nucleo-cytoplasmic shuttling of galectin-3. *Methods Mol Biol* 1207, 465-483
59. Nakahara S, Oka N, Wang Y, Hogan V, Inohara H and Raz A (2006) Characterization of the nuclear import pathways of galectin-3. *Cancer Res* 66, 9995-10006
60. Nakahara S, Hogan V, Inohara H and Raz A (2006) Importin-mediated nuclear translocation of galectin-3. *J Biol Chem* 281, 39649-39659
61. Davidson PJ, Li SY, Lohse AG et al (2006) Transport of galectin-3 between the nucleus and cytoplasm. I. Conditions and signals for nuclear import. *Glycobiology* 16, 602-611
62. Li SY, Davidson PJ, Lin NY, Patterson RJ, Wang JL and Arnoys EJ (2006) Transport of galectin-3 between the nucleus and cytoplasm. II. Identification of the signal for nuclear export. *Glycobiology* 16, 612-622
63. Kim SJ, Shin JY, Cheong TC et al (2011) Galectin-3 germline variant at position 191 enhances nuclear accumulation and activation of beta-catenin in gastric cancer. *Clin Exp Metastasis* 28, 743-750
64. Balan V, Nangia-Makker P, Schwartz AG et al (2008) Racial disparity in breast cancer and functional germ line mutation in galectin-3 (rs4644): a pilot study. *Cancer Res* 68, 10045-10050
65. Dagher SF, Wang JL and Patterson RJ (1995) Identification of galectin-3 as a factor in pre-mRNA splicing. *Proc Natl Acad Sci U S A* 92, 1213-1217
66. Inohara H, Akahani S and Raz A (1998) Galectin-3 stimulates cell proliferation. *Exp Cell Res* 245, 294-302
67. Bresalier RS, Mazurek N, Sternberg LR et al (1998) Metastasis of human colon cancer is altered by modifying expression of the beta-galactoside-binding protein galectin 3. *Gastroenterology* 115, 287-296
68. Takenaka Y, Fukumori T and Raz A (2004) Galectin-3 and metastasis. *Glycoconj J* 19, 543-549
69. Raz A, Zhu DG, Hogan V et al (1990) Evidence for the role of 34-kDa galactoside-binding lectin in transformation and metastasis. *Int J Cancer* 46, 871-877
70. Hood JD and Cheresh DA (2002) Role of integrins in cell invasion and migration. *Nat Rev Cancer* 2, 91-100
71. Yoder BJ, Tso E, Skacel M et al (2005) The expression of fascin, an actin-bundling motility protein, correlates with hormone receptor-negative breast cancer and a more aggressive clinical course. *Clin Cancer Res* 11, 186-192
72. Kureishy N, Sapountzi V, Prag S, Anilkumar N and Adams JC (2002) Fascins, and their roles in cell structure and function. *Bioessays* 24, 350-361
73. Hashimoto Y, Ito T, Inoue H et al (2005) Prognostic significance of fascin overexpression in human esophageal squamous cell carcinoma. *Clin Cancer Res* 11, 2597-2605
74. Jawhari AU, Buda A, Jenkins M et al (2003) Fascin, an actin-bundling protein, modulates colonic epithelial cell invasiveness and differentiation in vitro. *Am J Pathol* 162, 69-80
75. Grothey A, Hashizume R, Ji H et al (2000) C-erbB-2/HER-2 upregulates fascin, an actin-bundling protein associated with cell motility, in human breast cancer cell lines. *Oncogene* 19, 4864-4875
76. Hashimoto Y, Shimada Y, Kawamura J, Yamasaki S and Imamura M (2004) The prognostic relevance of fascin expression in human gastric carcinoma. *Oncology* 67, 262-270
77. Yamashiro S, Yamakita Y, Ono S and Matsumura F (1998) Fascin, an actin-bundling protein, induces membrane protrusions and increases cell motility of epithelial cells. *Mol Biol Cell* 9, 993-1006
78. Shonukan O, Bagayogo I, McCrear P, Chao M and Hempstead B (2003) Neurotrophin-induced melanoma cell migration is mediated through the actin-bundling protein fascin. *Oncogene* 22, 3616-3623
79. Shimura T, Takenaka Y, Tsutsumi S, Hogan V, Kikuchi A and Raz A (2004) Galectin-3, a novel binding partner of beta-catenin. *Cancer Res* 64, 6363-6367
80. Macfarlane SR, Seatter MJ, Kanke T, Hunter GD and Plevin R (2001) Proteinase-activated receptors. *Pharmacol Rev* 53, 245-282
81. Tellez C and Bar-Eli M (2003) Role and regulation of the thrombin receptor (PAR-1) in human melanoma. *Oncogene* 22, 3130-3137
82. Arora P, Ricks TK and Trejo J (2007) Protease-activated receptor signalling, endocytic sorting and dysregulation in cancer. *J Cell Sci* 120, 921-928
83. Pei D (2005) Matrix metalloproteinases target protease-activated receptors on the tumor cell surface. *Cancer Cell* 7, 207-208
84. Blackburn JS, Liu I, Coon CI and Brinckerhoff CE (2009) A matrix metalloproteinase-1/protease activated receptor-1 signaling axis promotes melanoma invasion and metastasis.

- Oncogene 28, 4237-4248
85. Song S, Byrd JC, Mazurek N, Liu K, Koo JS and Bresalier RS (2005) Galectin-3 modulates MUC2 mucin expression in human colon cancer cells at the level of transcription via AP-1 activation. *Gastroenterology* 129, 1581-1591
 86. Wilson NH and Key B (2007) Neogenin: one receptor, many functions. *Int J Biochem Cell Biol* 39, 874-878
 87. Kim SJ, Wang YG, Lee HW et al (2014) Up-regulation of neogenin-1 increases cell proliferation and motility in gastric cancer. *Oncotarget* 5, 3386-3398
 88. Li J, Shima H, Nishizawa H et al (2018) Phosphorylation of BACH1 switches its function from transcription factor to mitotic chromosome regulator and promotes its interaction with HMMR. *Biochem J* 475, 981-1002
 89. Yeh MH, Tzeng YJ, Fu TY et al (2018) Extracellular Matrix-receptor Interaction Signaling Genes Associated with Inferior Breast Cancer Survival. *Anticancer Res* 38, 4593-4605
 90. Casini P, Nardi I and Ori M (2010) RHAMM mRNA expression in proliferating and migrating cells of the developing central nervous system. *Gene Expr Patterns* 10, 93-97
 91. Bahrami SB, Tolg C, Peart T et al (2017) Receptor for hyaluronan mediated motility (RHAMM/HMMR) is a novel target for promoting subcutaneous adipogenesis. *Integr Biol (Camb)* 9, 223-237
 92. Connell M, Chen H, Jiang J et al (2017) HMMR acts in the PLK1-dependent spindle positioning pathway and supports neural development. *Elife* 6, pii: e28672
 93. Silverman AM, Nakata R, Shimada H, Sposto R and DeClerck YA (2012) A galectin-3-dependent pathway upregulates interleukin-6 in the microenvironment of human neuroblastoma. *Cancer Res* 72, 2228-2238
 94. Regalo G, Forster S, Resende C et al (2016) C/EBPbeta regulates homeostatic and oncogenic gastric cell proliferation. *J Mol Med (Berl)* 94, 1385-1395
 95. Vaught JB (2006) Biorepository and biospecimen science: a new focus for CEBP. *Cancer Epidemiol Biomarkers Prev* 15, 1572-1573
 96. Kuilman T, Michaloglou C, Mooi WJ and Peeper DS (2010) The essence of senescence. *Genes Dev* 24, 2463-2479
 97. Kim SJ, Lee HW, Gu Kang H et al (2014) Ablation of galectin-3 induces p27(KIP1)-dependent premature senescence without oncogenic stress. *Cell Death Differ* 21, 1769-1779
 98. La SH, Kim SJ, Kang HG, Lee HW and Chun KH (2016) Ablation of human telomerase reverse transcriptase (hTERT) induces cellular senescence in gastric cancer through a galectin-3 dependent mechanism. *Oncotarget* 7, 57117-57130
 99. Nangia-Makker P, Hogan V and Raz A (2018) Galectin-3 and cancer stemness. *Glycobiology* 28, 172-181
 100. Ma J, Yao Y, Wang P et al (2014) MiR-152 functions as a tumor suppressor in glioblastoma stem cells by targeting Kruppel-like factor 4. *Cancer Lett* 355, 85-95
 101. Seguin L, Kato S, Franovic A et al (2014) An integrin beta(3)-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition. *Nat Cell Biol* 16, 457-468
 102. Shekhar MP, Nangia-Makker P, Tait L, Miller F and Raz A (2004) Alterations in galectin-3 expression and distribution correlate with breast cancer progression: functional analysis of galectin-3 in breast epithelial-endothelial interactions. *Am J Pathol* 165, 1931-1941
 103. El Gendy H, Madkour B, Abdelaty S et al (2014) Galectin 3 for the diagnosis of bladder cancer. *Arab J Urol* 12, 178-181
 104. Yoshii T, Inohara H, Takenaka Y et al (2001) Galectin-3 maintains the transformed phenotype of thyroid papillary carcinoma cells. *Int J Oncol* 18, 787-792
 105. Nangia-Makker P, Balan V and Raz A (2008) Regulation of tumor progression by extracellular galectin-3. *Cancer Microenviron* 1, 43-51
 106. Chen WS, Cao Z, Leffler H, Nilsson UJ and Panjwani N (2017) Galectin-3 Inhibition by a Small-Molecule Inhibitor Reduces Both Pathological Corneal Neovascularization and Fibrosis. *Invest. Ophthalmol Vis Sci* 58, 9-20
 107. Glinkii OV, Sud S, Mossine VV et al (2012) Inhibition of prostate cancer bone metastasis by synthetic TF antigen mimic/galectin-3 inhibitor lactulose-L-leucine. *Neoplasia* 14, 65-73
 108. Campo VL, Marchiori MF, Rodrigues LC and Dias-Baruffi M (2016) Synthetic glycoconjugates inhibitors of tumor-related galectin-3: an update. *Glycoconj J* 33, 853-876
 109. Zetterberg FR, Peterson K, Johnsson RE et al (2018) Monosaccharide Derivatives with Low-Nanomolar Lectin Affinity and High Selectivity Based on Combined Fluorine-Amide, Phenyl-Arginine, Sulfur-pi, and Halogen Bond Interactions. *Chem Med Chem* 13, 133-137